Erbe Elektromedizin GmbH, a global leader in medical technology, have announced the clinical adoption of their latest hydrodissection and electrosurgical device – HYBRIDknife® flex. This is the first in human cases for the device, which was successfully used by Prof. Alessandro Repici and Prof. Roberta Maselli at Humanitas Research Hospital in Milan, Italy, to remove a 50×65 mm lateral spreading tumor in the cecum and a 35×40 mm lateral spreading tumor in the colon.
HYBRIDknife® flex combines needle-free, high-pressure hydrodissection and electrosurgical waveforms within the same device. This allows for the marking of lesions, layer-specific elevation of the submucosa, incision, dissection with endoCUT® and preciseSECT®, and if required, coagulation, all within the same instrument.
Mariuccia Zambelli, Vice President Global Marketing at Erbe Elektromedizin GmbH, commented: “We are very excited to announce the first in human cases with our latest addition to the Erbe HYBRIDknife® portfolio. An innovative instrument enabling high performance in advanced procedures […] We expect HYBRIDknife® flex to be commercially available in 2024.”
The HYBRIDknife® flex recently received the CE marking, and Erbe has submitted an application to the U.S. Food and Drug Administration (FDA) for regulatory approval.
Erbe Elektromedizin GmbH, a global leader in medical technology, have announced the clinical adoption of their latest hydrodissection and electrosurgical device – HYBRIDknife® flex. The device was successfully used by Prof. Alessandro Repici and Prof. Roberta Maselli at Humanitas Research Hospital in Milan, Italy, to remove two lesions en bloc without complications.
HYBRIDknife® flex combines needle-free, high-pressure hydrodissection and electrosurgical waveforms within the same device, allowing for the marking of lesions, layer-specific elevation of the submucosa, incision, dissection with endoCUT® and preciseSECT®, as well as coagulation, all within the same instrument.
Mariuccia Zambelli, Vice President Global Marketing at Erbe Elektromedizin GmbH, commented: “We are very excited to announce the first in human cases with our latest addition to the Erbe HYBRIDknife® portfolio. An innovative instrument enabling high performance in advanced procedures […] We expect HYBRIDknife® flex to be commercially available in 2024.”
The HYBRIDknife® flex recently received the CE marking, and Erbe has submitted an application to the U.S. Food and Drug Administration (FDA) for regulatory approval. This is set to expand the reach of this innovative instrument to healthcare professionals around the world.
The post Erbe Elektromedizin Launches HYBRIDknife® flex Instrument, Now CE Certified first appeared on BusinessMole.
